



Telix Pharmaceuticals Limited
ACN 616 620 369
Suite 401, 55 Flemington Road
North Melbourne
Victoria, 3051
Australia

**Webcast of CEO's presentation to
Jefferies 2019 London Healthcare Conference**

Melbourne (Australia) – 25th November 2019. Telix Pharmaceuticals Limited (ASX: TLX) has today announced that Group CEO, Dr Christian Behrenbruch, presented at Jefferies 2019 London Healthcare Conference. This year marks the 10th anniversary of now the largest healthcare-dedicated conference in Europe, which hosted over 500 participating companies, 2,000 attendees and 5,000 business-to-business and investor meetings.

The Jefferies 2019 London Healthcare Conference featured leading public and private companies from the pharmaceuticals, biotechnology, generics, consumer health, animal health, medical technology and healthcare services sectors from the United States, Europe, Africa, Middle East, Latin America, Russia, India, Israel, Australia, China and Japan.

Dr Behrenbruch presented on Telix's advanced clinical-stage portfolio of Molecularly Targeted Radiation (MTR) programs. Dr Behrenbruch's presentation can be viewed at the Jefferies London Healthcare Conference website at: <http://www.wsw.com/webcast/jeff123/tlx/>

About Telix Pharmaceuticals Limited

Telix Pharmaceuticals Limited is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). The company is headquartered in Melbourne with international operations in Brussels (EU), Kyoto (JP) and Indianapolis (US). Telix is developing a portfolio of clinical-stage oncology products that address significant unmet medical need in renal, prostate and brain (glioblastoma) cancer. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com.

Telix Corporate Contact

Dr Christian Behrenbruch
Telix Pharmaceuticals Limited
Chief Executive Officer
Email: chris@telixpharma.com

Telix Investor Relations

Dr David Cade
Telix Pharmaceuticals Limited
Chief Business Officer
Email: david.cade@telixpharma.com

Important Information

This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the "US Securities Act"), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the US Securities Act or an exemption from the registration requirements of the US Securities Act is available.